Monolaurin for Health & Longevity - Quick Reference Sheet
evipedia.aidev
← Back

Monolaurin for Health & Longevity

Created on 08/26/2026 – Quick Reference based on Evidence Review created using AI4L / Grok 4.5 – Audit

Monolaurin is a coconut- and milk-derived fat-like compound sold as an oral supplement. Laboratory work shows it can break the outer coating of selected bacteria, yeasts, and fatty-coated viruses. In people, only topical use has randomized evidence; swallowed monolaurin is untested against infection, inflammation, or aging. Not a demonstrated longevity intervention. (Full Review)

Protocol

Kabara / Lauricidin pellet titration
About 3 g two to three times daily
Sensitive users can start at a few pellets and build toward that amount
Capsule gram-dosing
600–1,000 mg capsules
Often started at one capsule twice daily with food, then increased
Time of day
Split morning and evening with meals
No circadian efficacy dataset; meals aid swallowing of a waxy lipid
Time to effect
Vaginal Candida and Gardnerella counts
Two days
0.5–5% gel twice daily
Staphylococcal exotoxin during tampon use
4–6 hours
Menstrual day 2 wear
Oral winter infections
Not trial-defined
Uncontrolled user timelines

Benefits

Contraindications
  • Known allergy to glyceryl laurate, glycerol monolaurate, or monolaurin
  • Pregnancy, until reproductive toxicology for supplemental doses is available
  • Clinically important immunosuppression when the goal is to preserve residual adaptive immunity (theoretical)
    •
Key Interactions
  • Prescription antimicrobials (penicillins, cephalosporins such as amoxicillin)
  • Immunosuppressants (tacrolimus, cyclosporine, systemic corticosteroids)
  • Over-the-counter antifungals and antibacterials (miconazole, bacitracin)
  • Probiotics and other antimicrobials (berberine, oregano oil)
  • Coconut oil and medium-chain triglyceride oils
  • Fat-soluble oral medications
    •

Risk & Side Effects

  • High:
  • Medium: Local urogenital irritation with vaginal gel
    •
  • Low: Skin irritation at high topical concentrations
    •
  • Speculative: Suppression of T-cell and B-cell signaling; metabolic syndrome and dysbiosis at low dietary doses; transient flu-like symptoms on rapid dose escalation; gastrointestinal intolerance with oral doses
    •

Monitoring

Marker Target Why
hs-CRP <1.0 mg/L (often <0.5 mg/L in prevention practice) Flags a systemic inflammatory shift
Fasting triglycerides <100 mg/dL functional; <150 mg/dL conventional Mouse low-dose monolaurin raised triglycerides
LDL cholesterol Context-dependent; many prevention clinics aim <100 mg/dL Rodent lipid shifts were diet-specific
Fasting glucose 70–90 mg/dL functional vs <100 mg/dL conventional Mouse glycemic markers were followed in feeding studies
Waist circumference Track change from personal baseline; no GML-specific target Mouse visceral-fat findings were directionally mixed

Cadence: Baseline before a first high-dose oral trial; repeat after the first 8–12 weeks, then every 6–12 months if use continues

Qualitative Assessment

  • Gastrointestinal comfort after dose increases (cramping, loose stool)
  • Frequency of winter respiratory or mucosal yeast flares relative to the person's own baseline
  • New or unusual infections if doses stay in the multi-gram range
  • Local burning or dermatitis if a topical product is added
Not medical advice. Educational distillation of a single evidence review. Confirm any decision with a qualified clinician, especially in the presence of prescription drugs or chronic conditions.